Publications

April 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (A)

By: Sandra J. Sucher and Stacy McManus

Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details

Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Pharmaceutical Industry

Article

Health Care Providers Need a Value Management Office

By: Robert S. Kaplan, Catherine H. MacLean, Alexander Dresner, Derek A. Haas and Thomas W. Feeley

Many health care organizations are striving to implement a value agenda that delivers better patient outcomes at lower cost, medical condition by medical condition. To accelerate the dissemination and adoption of the value agenda, across many more medical conditions,... View Details

Keywords: Service Delivery; Value; Health Care and Treatment; Health Industry

Register to Read

May 2009 (Revised August 2013)
Case

The DiagnoFirst Opportunity

By: Robert C. Pozen and Rukmini Balu

John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a genetic test that identified a subset of prostate cancer patients with a high risk of clinical... View Details

Keywords: Genetic Engineering; Genetically Modified; Genomics; Venture Capital; Patents; Genetics; Decision Choices and Conditions; Laws and Statutes; Investment; Science-Based Business; Biotechnology Industry

August 2001 (Revised August 2012)
Case

BestDoctors, Inc.

By: Regina E. Herzlinger and Seth Bokser

Upon learning the news of a critical illness, patients and their families are shocked, saddened, fearful, and angry all at once. And just as soon as they catch their collective breath, they all ask the same question—a question that has the potential to infuse hope into... View Details

Keywords: Business Model; Entrepreneurship; Health Care and Treatment; Medical Specialties; Knowledge Sharing; Demand and Consumers; Health Industry

Article

Defining the Value Framework for Prostate Brachytherapy Using Patient-Centered Outcome Metrics and Time-Driven Activity-Based Costing

By: N.G. Thaker, T.J. Pugh, U. Mahmood, S. Choi, T.E. Spinks, N.E. Martin, T.T. Sio, R.J. Kudchadker, R. S. Kaplan, D.A. Kuban, D.A. Swanson, P.F. Orio, M.J. Zelefsky, B.W. Cox, L. Potters, T.A. Buchholz, T.W. Feeley and S.J. Frank

PURPOSE: Value, defined as outcomes over costs, has been proposed as a measure to evaluate prostate cancer (PCa) treatments. We analyzed standardized outcomes and time-driven activity-based costing (TDABC) for prostate brachytherapy (PBT) to define a value... View Details

Find at Harvard

Register to Read

September 2011
Supplement

Expansion at Narayana Hrudayalaya

By: Tarun Khanna and Tanya Bijlani

Narayana Hrudayalaya has expanded into a multi-specialty health city in Bangalore, with a 25-acre campus that offers complex tertiary care procedures ranging from orthopedics to cancer care. In 2008, NH raised private equity from JP Morgan and Pinebridge Investments to... View Details

Keywords: Investment; Price; Health Care and Treatment; Emerging Markets; Social Enterprise; Expansion; Health Industry; Bangalore; Cayman Islands; Miami

2022
Case

Marathon Petroleum and Southwest Detroit: The Intersection of Community and Environment

By: Andrew J. Hoffman

Environmental racism describes the unequal burden of environmental hazards placed on disadvantaged communities through systems, policies, and practices. In such a situation, these people disproportionately live close to sources of toxic waste-what are referred to as... View Details

Keywords: Environmental Regulation; Pollutants; Pollution; Equality and Inequality; Social Issues; Poverty; Race; Health Disorders; Ethics

May 2025 (Revised May 2025)
Case

Daiichi Sankyo: Steering a Global Organization

By: Tiona Zuzul, Amy C. Edmondson and Cat Huang

In the spring of 2023, Sunao Manabe, CEO of Daiichi Sankyo, reflected on a pivotal decision. A large Western pharmaceutical company had made a bid to partner with Daiichi Sankyo to develop the next three products in its oncology pipeline. Daiichi Sankyo, a 125-year old... View Details

Keywords: Strategy; Culture Change; Decision-making; Leadership; Culture; Innovation; Psychological Safety

05 Sep 2023
Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

In the 1990s, after drugmaker Eli Lilly spent more than a decade and millions of dollars developing the new drug Alimta to treat lung cancer, the medication came up short in effectively treating cancer in expanded trials. While the... View Details

Keywords: by Michael Blanding

March 2021 (Revised January 2023)
Case

The Trouble with TCE

By: Vincent Pons, Rafael Di Tella and Galit Goldstein

Trichloroethylene, or TCE, was a chemical used by tens of thousands of businesses in the United States. It was an affordable tool for many. Yet, TCE had been associated with important health risks, including cancer and autoimmune disease. TCE potentially posed other... View Details

Keywords: Trichloroethylene; Toxicity; Lobbying; Chemicals; Health Disorders; Governing Rules, Regulations, and Reforms; Policy; Ethics; Business and Government Relations; Chemical Industry; United States

August 2023
Case

Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company

By: Satish Tadikonda and Brad Prosek

Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details

Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States

2022
Article

Improving Efficiency and Reducing Costs of MRI-Guided Prostate Brachytherapy Using Time-Driven Activity-Based Costing

By: Nikhil G. Thaker, Rajat J. Kudchadker, James R. Incalcaterra, Tharakeswara K. Bathala, Robert S. Kaplan, Ankit Agarwal, Deborah A. Kuban, Benjamin D. Frank, Prajnan Das, Thomas W. Feeley and Steven J. Frank

Integrated quality improvement (QI) and cost reduction strategies can help increase value in cancer care. We applied standard QI and TDABC methods to improve workflow efficiency and reduce costs for MRI-guided prostate brachytherapy. We constructed process maps,... View Details

Keywords: Brachytherapy; Quality Improvement; Prostate; Time-Driven Activity-Based Costing; Cost Accounting; Health Care and Treatment; Performance Efficiency; Health Industry

Read Now

January 2023
Case

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details

Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

Article

Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting

By: Raymond H. Mak, Michael G. Endres, Jin Hyun Paik, Rinat A. Sergeev, Hugo Aerts, Christopher L. Williams, Karim R. Lakhani and Eva C. Guinan

Importance: Radiation therapy (RT) is a critical cancer treatment, but the existing radiation oncologist work force does not meet growing global demand. One key physician task in RT planning involves tumor segmentation for targeting, which requires substantial... View Details

Keywords: Crowdsourcing; AI Algorithms; Health Care and Treatment; Collaborative Innovation and Invention; AI and Machine Learning

Find at Harvard

Read Now

March 2008 (Revised June 2008)
Case

The Broad Institute: Applying the Power of Genomics to Medicine

By: Vicki L. Sato and Rachel Gordon

In June 2003, Harvard University and MIT announced an unprecedented partnership to create a biomedical institute, The Broad Institute. The culture of the Broad centered on science, and those involved considered it to be at the edge of the scientific frontier. In just... View Details

Keywords: Education; Health Care and Treatment; Innovation Leadership; Growth and Development Strategy; Organizational Culture; Partners and Partnerships; Research and Development; Genetics

May 2012 (Revised August 2014)
Case

McKesson

By: Regina E. Herzlinger and Natalie Kindred

McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into... View Details

Keywords: Health Care Industry; Health Care Policy; Organizational Transformations; Health Services; Health Care and Treatment; Business Model; Service Operations; Change Management; Corporate Strategy; Information Technology; Policy; Pharmaceutical Industry; Health Industry; United States

March 2025 (Revised March 2025)
Case

Good for the Seller, Good for the Buyer and Good for Society: Sampo-yoshi, Sustainability and Trust at ITOCHU

By: Sandra J. Sucher and Bethelehem Y Araya

In 2024, ITOCHU CEO Masahiro Okafuji was at a crossroads. As the thirteenth CEO since ITOCHU’s founding in 1858, he had fueled the company’s growth since 2011 by bringing ITOCHU’s founding philosophy of Sampo-yoshi (good for the seller, good for the buyer and... View Details

Keywords: Sustainability; Trust; Profit; Growth and Development Strategy; Organizational Change and Adaptation; Mission and Purpose; Corporate Social Responsibility and Impact; Environmental Sustainability; Japan